Featured in Google Workspace’s upcoming Super Bowl ad, Travel Blogger and Accessibility Advocate Cory Lee is proving that ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Additional neurological features include peripheral neuropathies and dysfunction ... All patients diagnosed with spinal and bulbar muscular atrophy in Latvia (five unrelated Caucasian male patients) ...

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal ...

who are living with Spinal Muscular Atrophy (SMA) with the support of her mother, sister and teacher. Ms. Keya was felicitated by the Visakha Rasagna Vedika, a cultural organisation, at the Public ...

Seeking urgent Union government intervention to overcome the lack of affordable access to medicines for treating Spinal Muscular Atrophy (SMA) and the need to allow local manufacturers to make ...

What is SPINRAZA and its current approval status? SPINRAZA is an approved treatment for spinal muscular atrophy in over 71 countries, currently delivered at a dose of 12 mg. Disclaimer ...

The US Food and Drug Administration (FDA) has accepted Biogen’s supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the application for a higher dose regimen ...

Spinal muscular atrophy (SMA) is a rare hereditary neuromuscular disorder in which the spinal cord does not form normally. This inhibits voluntary muscle action, leading to a gradual decrease in ...